The European Medicines Agency (EMA) approved Sylvant (siltuximab) by Janssen on May 22, 2014, for the treatment of Multicentric Castleman's Disease (MCD). Sylvant is a targeted therapy, a biologic agent that directly binds to and neutralizes interleukin-6 (IL-6), a protein that promotes immune and inflammatory responses in the body. This approval is significant as it provides the first officially approved treatment option for patients in Europe who previously had to rely on highly toxic chemotherapy or temporary symptom-relieving steroids, as there were no other approved treatments available. This demonstrates the regulatory agency's commitment to addressing unmet medical needs in rare and difficult-to-treat hematological diseases through accelerated approval and orphan drug designation, showcasing the commercial success of global pharmaceutical companies.

The approval is based on data from the MCD2001 Phase 2 trial, a multinational, randomized study. Due to the rarity of MCD, the Phase 2 trial was accepted as a pivotal trial. The results showed that 34% of patients treated with Sylvant and best supportive care (BSC) experienced durable tumor reduction and symptom improvement, compared to 0% in the placebo group, demonstrating statistically significant efficacy. This data scientifically confirms that biologic targeted therapies can reliably improve survival rates and control clinical symptoms in rare and difficult-to-treat diseases, which was previously uncertain.

The approval of Sylvant marked a crucial step in securing a dominant commercial position in the European market. At the time, Roche's Rituximab was being used off-label, and Sylvant quickly became the standard of care upon approval. Although Roche's Tocilizumab, which targets the IL-6 receptor, was approved in some countries, including Japan, Sylvant was the only drug with official approval in Europe, giving it a significant first-mover advantage. This exclusivity has become a valuable commercial asset, contributing to the portfolio diversification of companies like Recordati and creating barriers to entry for competitors.

Subsequently, the commercial value of Sylvant has continued to increase through various licensing agreements and mergers and acquisitions (M&A) among multinational pharmaceutical companies. The original developer, Janssen, signed an agreement in 2018 to sell the global rights to Sylvant to EUSA Pharma, a global rare disease company, for $115 million. In 2021, Recordati, an Italian mid-sized pharmaceutical company, acquired EUSA Pharma for $845 million, making Sylvant a key asset in Recordati's rare disease business. In the first half of 2026 alone, Sylvant generated approximately €48.1 million in net sales, demonstrating its strong commercial presence and value creation in the global market.